Viking Therapeutics' current position is noteworthy for its strategic value, a rarity in the biotechnology sector. Obesity is no longer an experimental field; it has become a strategically critical and highly competitive battleground where major pharmaceutical companies are investing billions of dollars. Examples such as Pfizer agreeing to pay up to $7.3 billion for Metsera, and Roche paying billions of dollars for 89bio and Carmot, demonstrate the price major players are willing to pay to avoid being left behind in this market. In this context, Viking's market capitalization of approximately $4 billion, combined with its possession of a publicly traded and clean late-stage obesity platform, creates an extremely valuable strategic position. Being one of the few companies remaining in the public market with a late-stage, multi-option obesity pipeline makes Viking not just a biotech company, but a strategic asset poised to attract the attention of major pharmaceutical players.
The most critical element that sets Viking apart is the development of VK2735 in both injectable and oral forms. The injection program stands out for its efficacy and safety profile demonstrated in the Phase 2 VENTURE study; it achieved an average weight loss of up to 14.7% at the highest dose, and weight loss remained stable throughout the study. The glycemic improvements and positive effects on cardiometabolic parameters observed in prediabetic patients demonstrate that VK2735 not only provides weight loss but also offers potential for a broader metabolic disease platform. The transition of the injection program to Phase 2B with a monthly dosing regimen directly addresses challenges faced even by the most potent GLP-1 drugs on the market today, by improving patient compliance and ease of use.
On the other hand, the oral form offers an option that could overcome patient resistance to injections and dramatically expand the market. In the Phase 2 VENTURE-Oral study, an average weight loss of up to 12.2% was observed at the highest doses, clearly demonstrating a dose-dependent response. The oral form significantly enhances Viking's clinical and strategic value while improving patient access to and adherence to treatment. This combination shows that Viking isn't just creating value through a single program or molecule, but also possesses multiple sources of value; making the company, from an investor's perspective, an asset strongly fueled not only by clinical advancements but also by strategic opportunities. Looking at the stock, VKTX, trading around $35, is under pressure due to general risk aversion in the biotech sector and year-end position adjustments. Technical indicators such as intraday volatility, rejection from the 20 and 50-day moving averages, and struggling in the $34.5–$36 range are tiring for short-term investors.
However, what's really important for me is that the price doesn't reflect the whole story; because clinical data, Phase 3 program progress, and strategic potential haven't yet been fully priced in. There's a strong upside consensus among analysts; 12-month targets are above $90, and in more optimistic scenarios, point to $120–$125. This situation shows that the market is focusing on short-term catalyst deficiencies and volatility, failing to adequately consider long-term value. Risks and uncertainties are visible in the market; large and expensive Phase 3 programs, cash depletion, potential additional funding needs, and clinical risks fuel the stock's volatility. However, much of this risk is already priced in by the market, and what the price isn't adequately considering is the strategic importance of a clean, late-stage platform, valuable for a strategic player to own.
From an acquisition perspective, the most likely candidates are naturally large players strong in the obesity and metabolic disease field or looking to complement their portfolios: Novo Nordisk and Eli Lilly stand out; Roche and Pfizer could also get involved if they see a strategic opportunity. The strategic logic is simple: adding Viking's multi-option, late-stage platform to their portfolios provides rapid market entry and a competitive advantage. Even a $10 billion acquisition, with a current market capitalization of around $4 billion, would create a significant premium for investors and reward the stock with almost double its value in a short period. This creates a dramatic asymmetry for investors: either clinical data progresses and is reflected in pricing, or the market seizes an opportunity through a strategic purchase.
In conclusion, Viking Therapeutics' positioning, clinical progress, the advantages of VK2735 in both injectable and oral forms, market perception, and strategic acquisition potential make the stock attractive to long-term investors. Risks and uncertainties certainly exist; however, the market has already priced in most of these risks, and the strategic value is still not fully appreciated. The size of the obesity and metabolic disease market, combined with Viking's rare and clean platform, provides significant upside potential for the stock, both through organic value appreciation and a potential acquisition scenario. Following yesterday's Nova Nordisk news, other players will be scrambling to acquire Vikings Therapeutics. This asymmetry stands out as the key element that makes the risk worth taking. It is extremely risky.
